痴呆症患者的体重减轻：考虑药物治疗的潜在影响。
Weight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.
作者信息
Franx Bart A A, Arnoldussen Ilse A C, Kiliaan Amanda J, Gustafson Deborah R
机构信息
Department of Anatomy, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Neurology, Section for NeuroEpidemiology, State University of New York, Downstate Medical Center, 450 Clarkson Avenue, Box 1213, Brooklyn, NY, 11203, USA.
出版信息
Drugs Aging. 2017 Jun;34(6):425-436. doi: 10.1007/s40266-017-0462-x.
Abstract
Unintentional body weight loss is common in patients with dementia and is linked to cognitive impairment and poorer disease outcomes. It is proposed that some dementia medications with market approval, while aiming to improve cognitive and functional outcomes of a patient with dementia, are associated with reported body weight or body mass index loss. This review presents evidence in the published literature on body weight loss in dementia, describes selected theories behind body weight loss, evaluates the potential impact of approved dementia pharmacotherapies on body weight, considers the potential role for medical foods, understands the potential influence of treatments for neuropsychiatric symptoms and signs, and finally, summarizes this important area.
摘要
痴呆症患者中意外体重减轻很常见，且与认知障碍和较差的疾病预后相关。有人提出，一些已获市场批准的痴呆症药物，虽然旨在改善痴呆症患者的认知和功能预后，但却与报告的体重或体重指数下降有关。本综述展示了已发表文献中关于痴呆症患者体重减轻的证据，描述了体重减轻背后的一些理论，评估了已批准的痴呆症药物治疗对体重的潜在影响，考虑了医学食品的潜在作用，了解了针对神经精神症状和体征的治疗的潜在影响，最后，总结了这一重要领域。
相似文献
1
Weight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.痴呆症患者的体重减轻：考虑药物治疗的潜在影响。
Drugs Aging. 2017 Jun;34(6):425-436. doi: 10.1007/s40266-017-0462-x.
2
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.痴呆症药物的风险效益评估：证据的系统综述
Drugs Aging. 2015 Jun;32(6):453-67. doi: 10.1007/s40266-015-0266-9.
3
Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia.大麻素治疗痴呆的神经精神症状、疼痛和体重减轻。
Curr Opin Psychiatry. 2018 Mar;31(2):140-146. doi: 10.1097/YCO.0000000000000399.
5
Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.肥胖治疗的药理学演变：关注不良反应特征。
Diabetes Obes Metab. 2016 Jun;18(6):558-70. doi: 10.1111/dom.12657.
6
Cognitive impairment and dementia in late-life bipolar disorder.老年期双相障碍的认知障碍和痴呆。
Curr Opin Psychiatry. 2013 Jan;26(1):120-3. doi: 10.1097/YCO.0b013e32835ac5f6.
7
Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.银杏叶对认知障碍和痴呆的疗效及不良反应：一项系统评价和荟萃分析。
J Alzheimers Dis. 2015;43(2):589-603. doi: 10.3233/JAD-140837.
8
Cognitive Effects of Intentional Weight Loss in Elderly Obese Individuals With Mild Cognitive Impairment.轻度认知障碍老年肥胖个体有意减肥的认知影响
J Clin Endocrinol Metab. 2016 Mar;101(3):1104-12. doi: 10.1210/jc.2015-2315. Epub 2015 Dec 29.
9
Procaine treatments for cognition and dementia.用于认知和痴呆症的普鲁卡因治疗方法。
Cochrane Database Syst Rev. 2008 Oct 8(4):CD005993. doi: 10.1002/14651858.CD005993.pub2.
10
Adverse drug reactions in elderly patients with cognitive disorders: A systematic review.认知障碍老年患者的药物不良反应：一项系统评价。
Maturitas. 2016 Mar;85:56-63. doi: 10.1016/j.maturitas.2015.12.013. Epub 2015 Dec 29.
引用本文的文献
1
Body weight trajectories from midlife are associated with cognitive decline in advanced age.从中年期开始的体重轨迹与老年期的认知衰退有关。
Sci Rep. 2025 Jul 6;15(1):24128. doi: 10.1038/s41598-025-08725-5.
2
Alzheimer's subtypes A supervised, unsupervised, multimodal, multilayered embedded recursive (SUMMER) AI study.阿尔茨海默病亚型：一项监督式、非监督式、多模态、多层嵌入式递归（SUMMER）人工智能研究。
bioRxiv. 2025 May 14:2025.05.09.653177. doi: 10.1101/2025.05.09.653177.
3
Nutrition: A non-negligible factor in the pathogenesis and treatment of Alzheimer's disease.营养：阿尔茨海默病发病机制与治疗中不可忽视的因素。
Alzheimers Dement. 2025 Feb;21(2):e14547. doi: 10.1002/alz.14547. Epub 2025 Jan 27.
4
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.EVOKE和EVOKE+：两项大型、双盲、安慰剂对照的3期研究设计，评估司美格鲁肽在早期有症状阿尔茨海默病中的疗效、安全性和耐受性。
Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7.
5
Neuro-Adipokine Crosstalk in Alzheimer's Disease.神经-脂肪因子串扰在阿尔茨海默病中的作用。
Int J Mol Sci. 2024 May 29;25(11):5932. doi: 10.3390/ijms25115932.
6
The impact of continuous and intermittent ketogenic diets on cognitive behavior, motor function, and blood lipids in TgF344-AD rats.持续和间歇性生酮饮食对TgF344-AD大鼠认知行为、运动功能和血脂的影响。
Aging (Albany NY). 2024 Apr 12;16(7):5811-5828. doi: 10.18632/aging.205741.
7
Galantamine improves glycemic control and diabetic nephropathy in Lepr mice.加兰他敏改善 Lepr 小鼠的血糖控制和糖尿病肾病。
Sci Rep. 2023 Sep 20;13(1):15544. doi: 10.1038/s41598-023-42665-2.
8
Time Path of Weight Status Before and After Incident Dementia.事件性痴呆前后体重状况的时间路径。
J Aging Health. 2024 Jan;36(1-2):98-109. doi: 10.1177/08982643231170711. Epub 2023 May 4.
9
Risk of dementia associated with body mass index, changes in body weight and waist circumference in older people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study.2 型糖尿病老年人的体重指数、体重变化和腰围与痴呆风险的关系：爱丁堡 2 型糖尿病研究。
Diabet Med. 2023 May;40(5):e15063. doi: 10.1111/dme.15063. Epub 2023 Mar 3.
10
Auditory-limbic-cerebellum interactions and cognitive impairments in noise-induced hearing loss.听觉-边缘-小脑相互作用与噪声性听力损失的认知障碍。
CNS Neurosci Ther. 2023 Mar;29(3):932-940. doi: 10.1111/cns.14028. Epub 2022 Nov 15.
本文引用的文献
1
Body Mass Index, Waist Circumference, and Mortality in a Large Multiethnic Postmenopausal Cohort-Results from the Women's Health Initiative.大型多民族绝经后队列中的体重指数、腰围与死亡率——来自女性健康倡议的结果
J Am Geriatr Soc. 2017 Sep;65(9):1907-1915. doi: 10.1111/jgs.14790. Epub 2017 Feb 23.
2
Combined associations of body weight and lifestyle factors with all cause and cause specific mortality in men and women: prospective cohort study.体重与生活方式因素对男性和女性全因死亡率及特定病因死亡率的综合影响：前瞻性队列研究
BMJ. 2016 Nov 24;355:i5855. doi: 10.1136/bmj.i5855.
3
Novel Therapy of Hyperhomocysteinemia in Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementing Disorders.轻度认知障碍、阿尔茨海默病及其他痴呆症中高同型半胱氨酸血症的新型疗法。
J Nutr Health Aging. 2016;20(8):825-834. doi: 10.1007/s12603-016-0688-z.
4
H1-histamine receptor affinity predicts weight gain with antidepressants.H1组胺受体亲和力可预测抗抑郁药导致的体重增加。
Eur Neuropsychopharmacol. 2016 Oct;26(10):1673-7. doi: 10.1016/j.euroneuro.2016.08.012. Epub 2016 Sep 1.
5
The worldwide costs of dementia 2015 and comparisons with 2010.2015年全球痴呆症成本及与2010年的比较。
Alzheimers Dement. 2017 Jan;13(1):1-7. doi: 10.1016/j.jalz.2016.07.150. Epub 2016 Aug 29.
6
Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis.乙酰胆碱酯酶抑制剂与老年痴呆症患者体重减轻相关：系统评价和荟萃分析。
J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1368-1374. doi: 10.1136/jnnp-2016-313660. Epub 2016 Jun 3.
7
A Dietary Treatment Improves Cerebral Blood Flow and Brain Connectivity in Aging apoE4 Mice.饮食疗法改善衰老的载脂蛋白E4小鼠的脑血流量和脑连接性。
Neural Plast. 2016;2016:6846721. doi: 10.1155/2016/6846721. Epub 2016 Mar 10.
8
Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer's Disease.体重减轻预示着轻度认知障碍向阿尔茨海默病的进展。
PLoS One. 2016 Mar 18;11(3):e0151710. doi: 10.1371/journal.pone.0151710. eCollection 2016.
9
Incidence of antidepressant use in community-dwelling persons with and without Alzheimer's disease: 13-year follow-up.社区居住的阿尔茨海默病患者和非阿尔茨海默病患者中抗抑郁药使用的发生率：13 年随访。
Int J Geriatr Psychiatry. 2017 Jan;32(1):94-101. doi: 10.1002/gps.4450. Epub 2016 Feb 28.
10
Decline in Weight and Incident Mild Cognitive Impairment: Mayo Clinic Study of Aging.体重下降与轻度认知障碍的发生：梅奥诊所衰老研究
JAMA Neurol. 2016 Apr;73(4):439-46. doi: 10.1001/jamaneurol.2015.4756.
Zotero 插件